Phase II trial of erlotinib during and after radiotherapy in children with newly diagnosed high-grade gliomas

Frontiers in Oncology

Volumn 4 APR, Issue , 2014, Pages

  Qaddoumi, Ibrahim ^a,b   Kocak, Mehmet ^a,b   Pai Panandiker, Atmaram S ^a   Armstrong, Gregory T ^a   Wetmore, Cynthia ^a,b   Crawford, John R ^c   Lin, Tong ^a   Boyett, James M ^a   Kun, Larry E ^a   Boop, Fredrick A ^d   Merchant, Thomas E ^a   Ellison, David W ^a   Gajjar, Amar ^a,b   Broniscer, Alberto ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SEMMES MURPHEY NEUROLOGIC AND SPINE INSTITUTE   (United States)

Author keywords

Epidermal growth factor receptor; Erlotinib; High grade glioma; Pediatric; Phase II; Radiotherapy

Indexed keywords

DEXAMETHASONE; ERLOTINIB;

ADOLESCENT; ADULT; ANOREXIA; ARTICLE; ASTROCYTOMA; BRAIN METASTASIS; CANCER SURGERY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; GLIOBLASTOMA; GLIOMA; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; INTRACRANIAL ANAPLASTIC ASTROCYTOMA; LIVER DISEASE; MALE; METABOLIC DISORDER; MORTALITY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OVERALL SURVIVAL; PANCREATITIS; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PRURITUS; RADIATION DOSE; RASH; RECOMMENDED DRUG DOSE; SKIN DISEASE; SPINE METASTASIS; TUMOR GROWTH; WEIGHT REDUCTION;

EID: 84900992989     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00067     Document Type: Article

References (29)

1. Broniscer A, Gajjar A. Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist (2004) 9:196-7. doi:10.1634/theoncologist.9-2-197.
2. Finlay JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Children's Cancer Group. J Clin Oncol (1995) 13:112-23.
3. Broniscer A, Chintagumpala M, Fouladi M, Krasin MJ, Kocak M, Bowers DC, et al. Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol (2006) 76:313-9. doi:10.1007/s11060-005-7409-5.
4. Cohen KJ, Pollack IF, Zhou T, Buxton A, Holmes EJ, Burger PC, et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol (2011) 13:317-23. doi:10.1093/neuonc/noq191.
5. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol (1995) 19:132-83. doi:10.1016/1040-8428(94)00144-I.
6. Raizer JJ. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J Neurooncol (2005) 74:76-7. doi:10.1007/s11060-005-0603-7.
7. Dhomen NS, Mariadason J, Tebbutt N, Scott AM. Therapeutic targeting of the epidermal growth factor receptor in human cancer. Crit Rev Oncog (2012) 17:31-50. doi:10.1615/CritRevOncog.v17.i1.40.
8. Norman P. OSI-774 OSI Pharmaceuticals. Curr Opin Investig Drugs (2001) 2:298-304.
9. Sung T, Miller DC, Hayes RL, Alonso M, Yee H, Newcomb EW. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol (2000) 10:249-59. doi:10.1111/j.1750-3639.2000.tb00258.x.
10. Pollack IF, Hamilton RL, James CD, Finkelstein SD, Burnham J, Yates AJ, et al. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. J Neurosurg (2006) 105(5 Suppl):418-24. doi:10.3171/ped.2006.105.5.418.
11. Bredel M, Pollack IF, Hamilton RL, James CD. Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res (1999) 5:1786-92.
12. Prados MD, Lamborn KR, Chang S, Burton E, Butowski N, Malec M, et al. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol (2006) 8:67-8. doi:10.1215/S1522851705000451.
13. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 353:2012-24. doi:10.1056/NEJMoa051918.
14. Broniscer A, Baker SJ, Stewart CF, Merchant TE, Laningham FH, Schaiquevich P, et al. Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. Clin Cancer Res (2009) 15:701-7. doi:10.1158/1078-0432.CCR-08-1923.
15. Piantadosi S. Clinical Trials: A Methodologic Perspective. Wiley Series in Probability and Statistics. New Jersey: John Wiley & Sons, Inc (1997). 238 p.
16. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 352:987-96. doi:10.1056/NEJMoa043330.
17. Armstrong GT, Phillips PC, Rorke-Adams LB, Judkins AR, Localio AR, Fisher MJ. Gliomatosis cerebri: 20 years of experience at the Children's Hospital of Philadelphia. Cancer (2006) 107:1597-606. doi:10.1002/cncr.22210.
18. Kramm CM, Butenhoff S, Rausche U, Warmuth-Metz M, Kortmann RD, Pietsch T, et al. Thalamic high-grade gliomas in children: a distinct clinical subset? Neuro Oncol (2011) 13:680-9. doi:10.1093/neuonc/nor045.
19. Jakacki RI, Hamilton M, Gilbertson RJ, Blaney SM, Tersak J, Krailo MD, et al. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol (2008) 26:4921-7. doi:10.1200/JCO.2007.15.2306.
20. Geoerger B, Hargrave D, Thomas F, Ndiaye A, Frappaz D, Andreiuolo F, et al. Innovative therapies for children with cancer: pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol (2011) 13:109-18. doi:10.1093/neuonc/noq141.
21. van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol (2009) 27:1268-74. doi:10.1200/JCO.2008.17.5984.
22. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol (2010) 12:93-5. doi:10.1093/neuonc/nop017.
23. Ruinemans GM, Balemans C, Mattijssen V, Wiersma-van Tilburg AJ, Smit HJ. Fatal necrotizing pancreatitis during combined treatment with erlotinib and sunitinib. Lung Cancer (2010) 70:364-5. doi:10.1016/j.lungcan.2010.08.004.
24. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 356:115-24. doi:10.1056/NEJMoa065044.
25. Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst (2005) 97:880-7. doi:10.1093/jnci/dji161.
26. Bax DA, Gaspar N, Little SE, Marshall L, Perryman L, Regairaz M, et al. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clin Cancer Res (2009) 15:5753-61. doi:10.1158/1078-0432.CCR-08-3210.
27. Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, Zhang J, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol (2010) 28:3061-8. doi:10.1200/JCO.2009.26.7252.
28. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 482:226-31. doi:10.1038/nature10833.
29. Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, et al. St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 44:251-3. doi:10.1038/ng.1102.